You have right Stina,
According to a McKinsey study analyzing phase 3 trial failures reported from 1990-2002, the results had numerous implications for pharma.Focusing on small-molecules (656 Phase 3 compounds), 58% were successful.This of course implies a 42% failure rate; a staggering sum...